ACUTUS MEDICAL INC (AFIB)
US0051111096 - Common Stock
We assign a fundamental rating of 2 out of 10 to AFIB. AFIB was compared to 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of AFIB have multiple concerns. AFIB is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
AFIB had negative earnings in the past year.
AFIB had a negative operating cash flow in the past year.
AFIB had negative earnings in each of the past 5 years.
In the past 5 years AFIB always reported negative operating cash flow.
1.2 Ratios
AFIB has a Return On Assets of -38.71%. This is in the lower half of the industry: AFIB underperforms 61.46% of its industry peers.
With a Return On Equity value of -103.44%, AFIB is not doing good in the industry: 71.35% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.71% | ||
| ROE | -103.44% | ||
| ROIC | N/A |
ROA(3y)-50.66%
ROA(5y)-85.79%
ROE(3y)-81.57%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AFIB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AFIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AFIB has more shares outstanding
AFIB has a worse debt/assets ratio than last year.
2.2 Solvency
AFIB has an Altman-Z score of -11.05. This is a bad value and indicates that AFIB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AFIB (-11.05) is worse than 81.25% of its industry peers.
AFIB has a Debt/Equity ratio of 1.10. This is a high value indicating a heavy dependency on external financing.
AFIB has a worse Debt to Equity ratio (1.10) than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.05 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
A Current Ratio of 4.92 indicates that AFIB has no problem at all paying its short term obligations.
AFIB's Current ratio of 4.92 is fine compared to the rest of the industry. AFIB outperforms 69.27% of its industry peers.
A Quick Ratio of 3.85 indicates that AFIB has no problem at all paying its short term obligations.
AFIB has a Quick ratio of 3.85. This is in the better half of the industry: AFIB outperforms 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.92 | ||
| Quick Ratio | 3.85 |
3. Growth
3.1 Past
AFIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.62%, which is quite impressive.
AFIB shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.73%.
AFIB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.26% yearly.
EPS 1Y (TTM)70.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q37.5%
Revenue 1Y (TTM)24.73%
Revenue growth 3Y79.26%
Revenue growth 5YN/A
Revenue growth Q2Q43.9%
3.2 Future
Based on estimates for the next years, AFIB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.68% on average per year.
The Revenue is expected to grow by 59.26% on average over the next years. This is a very strong growth
EPS Next Y12.16%
EPS Next 2Y15.17%
EPS Next 3Y13.68%
EPS Next 5YN/A
Revenue Next Year31.1%
Revenue Next 2Y41.69%
Revenue Next 3Y46.08%
Revenue Next 5Y59.26%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AFIB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFIB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AFIB's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.17%
EPS Next 3Y13.68%
5. Dividend
5.1 Amount
AFIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACUTUS MEDICAL INC
NASDAQ:AFIB (5/1/2024, 7:00:00 PM)
After market: 0.1534 +0 (+0.26%)0.153
+0 (+2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.55M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.71% | ||
| ROE | -103.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.92 | ||
| Quick Ratio | 3.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)70.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.73%
Revenue growth 3Y79.26%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y